Outlook Therapeutics® Announces UK Mhra Marketing Authorization of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
outlook therapeutics®宣佈Lytenava™(Bevacizumab Gamma)獲得英國MHRA批准,用於治療溼性年齡相關性黃斑變性
Outlook Therapeutics® Announces UK Mhra Marketing Authorization of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
outlook therapeutics®宣佈Lytenava™(Bevacizumab Gamma)獲得英國MHRA批准,用於治療溼性年齡相關性黃斑變性
譯文內容由第三人軟體翻譯。